Artiva Biotherapeutics (ARTV) Jefferies Global Healthcare Conference 2026 summary

Strategic positioning and market opportunity

• Deep B-cell depletion and auto CAR-T therapies in autoimmunity are attracting significant industry interest, with many pharmaceutical companies pursuing multiple programs in this space.

• The focus is on being first to market in indications with high unmet need, particularly two-plus refractory rheumatoid arthritis (RA), where 25% of patients become refractory to two mechanisms and face limited options.

• The target population is large, with $5 billion spent annually on refractory RA patients who have low response rates (10%-20% ACR50) to current therapies.

• The therapy is designed for ease of use in community settings, resembling biologics in administration and accessibility.

• Strategic site expansion in the US, Europe, and Latin America supports efficient trial enrollment and future market access.

Clinical data highlights and competitive differentiation

• Recent data on 37 autoimmune patients (over 70 treated to date) show consistent, high efficacy across RA, Sjögren's, scleroderma, and lymphomas, with a notably high ACR50 response rate in refractory RA.

• Durability is a key differentiator: many patients remain treatment-free for 12–24 months after a single infusion, with no relapses observed yet.

• The therapy offers a one-time treatment with the potential for re-dosing, contrasting with chronic immunosuppressive regimens.

• Side effect profile is favorable, with most adverse events attributable to rituximab and low-dose Cy/Flu, and infection rates remain low due to prophylaxis.

• Data from the EULAR conference provide further detail on efficacy and safety, especially in Sjögren's, supporting the therapy's broad potential.

Pivotal trial design and regulatory pathway

• FDA alignment achieved for a single pivotal randomized controlled trial (RCT) in refractory RA, comparing the therapy to rituximab in 150 patients (2:1 randomization), with ACR50 at six months as the primary endpoint.

• Patients failing rituximab will roll over to the therapy arm, enabling robust efficacy comparisons.

• Trial initiation is planned for the second half of 2024, with readout expected in the second half of 2028.

• No major gating factors remain; over 40 sites are already active, with plans to expand to 80 for efficient enrollment.

• The BLA will be based on the six-month primary endpoint, with durability and safety data from ongoing basket studies supplementing the regulatory package.